Antidiabetic characteristics of dehydroepiandrosterone in animal and human studies

  • Margot P. Cleary
Part of the Rev.Ser.Advs.Research Diab.Animals (Birkhäuser) book series (RSARDA, volume 6)

Abstract

Interest in dehydroepiandrosterone (DHEA) as a metabolic factor involved with diabetes in relation to obesity dates back to a study published by Šonka and coworkers1 30 years ago. They reported that no DHEA was detected in the urine of 27 of 32 elderly obese diabetic subjects. This and other studies led Šonka2 to the speculation that DHEA, a 17-ketosteroid produced in the adrenal gland, may have important regulatory functions in the body. Since these early observations were made, ameliorative effects resulting from the administration of DHEA were obtained in numerous studies. Most studies have used mice and rats, but additional work has been presented in dogs, monkeys, rabbits, and humans. An array of effects was attributed to DHEA treatment, including prevention of cancer, aging, obesity, viral diseases, and atherosclerosis.3–6 Following in Šonka’s path there have also been further investigations into the role of DHEA as an antidiabetic agent. My overview of the literature is pertinent to this potential characteristic of DHEA.

Key words

obesity insulin glucose tolerance insulin resistance mice rats humans 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Šonka J, Gregorova I, Pav J, Skrha F. Dehydroepiandrosterone in obese diabetics. Lancet 2:44–5, 1964.Google Scholar
  2. 2.
    Šonka J. Dehydroepiandrosterone metabolic effects. Acta Univ Carol Med Monogr 71:1–171, 1976.PubMedGoogle Scholar
  3. 3.
    Kalimi M, Regelson W. The biologic role of dehydroepiandrosterone (DHEA). Walter de Gruyter, New York, 1990.Google Scholar
  4. 4.
    Gordon GB, Schantz LM, Talalay P. Modulation of growth, differentiation and carcinogenesis by dehydroepiandrosterone. Adv Enzyme Regul 26:355–82, 1987.PubMedGoogle Scholar
  5. 5.
    Cleary MP. The antiobesity effect of dehydroepiandrosterone in rats. Proc Soc Exp Biol Med 196:8–16, 1991.PubMedGoogle Scholar
  6. 6.
    Berdanier CD, Parente JA Jr, Mcintosh MK. Is dehydroepiandrosterone an antiobesity agent? FASEB J 7:414–9, 1993.PubMedGoogle Scholar
  7. 7.
    Yen TT, Allan JA, Pearson DV, Acton JM. Prevention of obesity in Avy/a mice by dehydroepiandrosterone. Lipids 12:409–13, 1977.PubMedGoogle Scholar
  8. 8.
    Schwartz AG. Inhibition of spontaneous breast cancer formation in female C3H (Avy/a) mice by long term treatment with dehydroepiandrosterone. Cancer Res 39:1129–32, 1979.PubMedGoogle Scholar
  9. 9.
    Weindruch R, Meetus G, Walford RL. Food intake reduction and immunologic alterations in mice fed dehydroepiandrosterone. Exp Gerontol 19:297–304, 1984.PubMedGoogle Scholar
  10. 10.
    Cleary MP, Seidenstat R, Tannen RH, Schwartz AG. The effect of dehydroepiandrosterone on adipose tissue cellularity in mice. Proc Soc Exp Biol Med 171:276–84, 1982.PubMedGoogle Scholar
  11. 11.
    Granholm NH, Staber LD, Wilken PJ. Effects of dehydroepiandrosterone on obesity and glucose-6-phosphate dehydrogenase activity in the lethal yellow mouse (strain 129/Sv-Ay/Aw). J Exp Zool 242:67–74, 1987.PubMedGoogle Scholar
  12. 12.
    Pashko LL, Fairman DK, Schwartz AG. Inhibition of proteinuria development in aging Sprague-Dawley rats and C57BL/6 mice by long-term treatment with dehydroepiandrosterone. J Gerontol 41:433–8, 1986.PubMedGoogle Scholar
  13. 13.
    Coleman DL, Leiter EH, Schwizer RW. Therapeutic effects of dehydroepiandrosterone (DHEA) in diabetic mice. Diabetes 31:830–3, 1982.PubMedGoogle Scholar
  14. 14.
    Coleman DL, Schwizer RW, Leiter EH. Effect of genetic background on the therapeutic effects of dehydroepiandrosterone (DHEA) in diabetes-obesity mutants and in aged normal mice. Diabetes 33:26–32, 1984.PubMedGoogle Scholar
  15. 15.
    Coleman DL, Leiter EH, Applezweig N. Therapeutic effects of dehydroepiandrosterone metabolites in diabetes mutant mice (C56BL/K-db/db). Endocrinology 115:239–43, 1984.PubMedGoogle Scholar
  16. 16.
    Coleman DL. Antiobesity effects of etiocholanolones in diabetes (db), viable yellow (Avy), and normal mice. Endocrinology 117:2279–83, 1985.PubMedGoogle Scholar
  17. 17.
    Leiter EH, Beamer WG, Coleman DL, Longcope C. Androgenic and estrogenic metabolites in serum of mice fed dehydroepiandrosterone: Relationship to antihyperglycemic effects. Metabolism 36:863–9, 1987.PubMedGoogle Scholar
  18. 18.
    Beamer WG, Shultz KL, Tennent BJ. Induction of ovarian granulosa cell tumors in SWXJ-9 mice with dehydroepiandrosterone. Cancer Res 48:2788–92, 1988.PubMedGoogle Scholar
  19. 19.
    Tennent BJ, Shultz KL, Beamer WG. Genetic susceptibility for C19 androgen induction of ovarian granulosa cell tumorigenesis in SWXJ strains of mice. Cancer Res 53:1059–63, 1993.PubMedGoogle Scholar
  20. 20.
    Schwartz AG, Lewbart ML, Pashko LL. Novel dehydroepiandrosterone analogues with enhanced biological activity and reduced side effects in mice and rats. Cancer Res 48:4817–22, 1988.PubMedGoogle Scholar
  21. 21.
    Pashko LL, Schwarz AG. Antihyperglycemic effect of dehydroepiandrosterone analogue 16±-fluoro-5-androsten-17-one in diabetic mice. Diabetes 42:1105–8, 1993.PubMedGoogle Scholar
  22. 22.
    Cleary MP, Shepherd A, Jenks B. Effect of dehydroepiandrosterone on growth in lean and obese Zucker rats. J Nutr 114:1242–51, 1984.PubMedGoogle Scholar
  23. 23.
    Shepherd A, Cleary MP. Metabolic alterations due to dehydroepiandrosterone in the obese Zucker rat. Am J Physiol 246:E123–8, 1984.PubMedGoogle Scholar
  24. 24.
    Cleary MP, Billheimer J, Finan A, et al. Metabolic consequences of dehydroepiandrosterone in lean and obese adult Zucker rats. Horm Metab Res 16(Suppl 1):43–6, 1984.PubMedGoogle Scholar
  25. 25.
    Cleary MP, Zisk JR. Antiobesity effect of two different levels of dehydroepiandrosterone treatment in lean and obese middle-aged female Zucker rats. Int J Obes 10:193–204, 1986.PubMedGoogle Scholar
  26. 26.
    Muller S, Cleary MP. Glucose metabolism in isolated adipocytes from lean and obese Zucker rats following treatment with dehydroepiandrosterone. Metabolism 34:278–84, 1985.PubMedGoogle Scholar
  27. 27.
    Svec F, Hilton CW, Wright B, et al. The effect of DHEA given chronically to Zucker rats. Proc Soc Exp Biol Med 209:92–7, 1995.PubMedGoogle Scholar
  28. 28.
    Gansler TS, Muller S, Cleary MP. Chronic administration of dehydroepiandrosterone (DHEA) reduces pancreatic b-cell hyperplasia and hyperinsulinemia in genetically obese rats. Proc Soc Exp Biol Med 180:155–62, 1985.PubMedGoogle Scholar
  29. 29.
    Cleary MP, Zabel T, Sartin JL. Effects of short-term dehydroepiandrosterone treatment on serum and pancreatic insulin in Zucker rats. J Nutr 118:382–7, 1988.PubMedGoogle Scholar
  30. 30.
    Mohan PF, Cleary MP. Comparisons of dehydroepiandrosterone and clofrbric acid treatments in obese Zucker rats. J Nutr 119:496–501, 1989.PubMedGoogle Scholar
  31. 31.
    Hayek A, Woodside W. Correlation between morphology and function in isolated islets of the Zucker rat. Diabetes 28:565–9, 1979.PubMedGoogle Scholar
  32. 32.
    Cleary MP. Effect of dehydroepiandrosterone treatment on liver metabolism in rats. Int J Biochem 22:305–10, 1990.Google Scholar
  33. 33.
    Marks PA, Banks J. Inhibition of mammalian glucose-6-phosphate dehydrogenase by steroid hormones. Proc Natl Acad Sci USA 46:447–52, 1960.PubMedGoogle Scholar
  34. 34.
    Oertel GW, Benes P. The effects of steroids on glucose-6-phosphate dehydrogenase. J Steroid Biochem 3:493–6, 1972.PubMedGoogle Scholar
  35. 35.
    Beitner R, Naor Z. The effect of adenine nucleotides and dehydroepiandrosterone on the isoenzymes of NADP+-and NAD+-glucose 6-phosphate dehydrogenase and 6-phosphogluconate dehydrogenase from rat adipose tissue. Biochim Biophys Acta 286:437–40, 1972.PubMedGoogle Scholar
  36. 36.
    Hissin PJ, Foley JE, Wardzala LJ, et al. Mechanism of insulin-resistant glucose transport activity in the enlarged adipose cell of the aged, obese rat. Relative depletion of intracellular glucose transport systems. J Clin Invest 70:780–90, 1982.PubMedGoogle Scholar
  37. 37.
    Richardson DK, Czech MP. Diminished activities of fatty acid synthesis enzymes in insulin-resistant adipocytes from spontaneously obese rats. Horm Metab Res 11:427–31, 1979.PubMedGoogle Scholar
  38. 38.
    Olefsky JM. The effect of spontaneous obesity on insulin binding, glucose transport and glucose oxidation of isolated rat adipocytes. J Clin Invest 57:842–51, 1976.PubMedGoogle Scholar
  39. 39.
    Mohan PF, Ihnen JS, Levin BE, Cleary MP. Effects of dehydroepiandrosterone treatment in rats with diet-induced obesity. J Nutr 120:1103–14, 1990.PubMedGoogle Scholar
  40. 40.
    Berdanier CD. The BHE rat: An animal model for the study of noninsulin-dependent diabetes mellitus. FASEB J 5:2139–4, 1991.PubMedGoogle Scholar
  41. 41.
    McIntosh MK, Berdanier CD. Antiobesity effects of dehydroepiandrosterone are mediated be futile substrate cycling in hepatocytes of BHE/cdb rats. J Nutr 121:2037–13, 1991.PubMedGoogle Scholar
  42. 42.
    Roy S, Mahesh VB, Greenblatt RB. Effect of dehydroepiandrosterone and D4-an-drostenedione on the reproductive organ of female rats; production of cystic changes in the ovary. Nature 196:2–5, 1962.Google Scholar
  43. 43.
    Parker CR, Mahesh VB. Interrelationship between excessive levels of circulatory androgens in the blood and ovulatory failure. J Reprod Med 17:75–90, 1976.PubMedGoogle Scholar
  44. 44.
    Lee M-T, Anderson E, Lee GY. Changes in ovarian morphology and serum hormones in the rat after treatment with dehydroepiandrosterone. Anat Rec 231:185–92, 1991.PubMedGoogle Scholar
  45. 45.
    Nestler JE, Barlascini CO, Clore JN, Blackard WG. Dehydroepiandrosterone reduces serum low density lipoprotein levels and body fat but does not alter insulin sensitivity in normal men. J Clin Endocr Metab 66:57–61, 1988.PubMedGoogle Scholar
  46. 46.
    Usiskin KB, Butterworth S, Clore JN, et al. Lack of effect of dehydroepiandrosterone in obese men. Int J Obes 14:457–63, 1990.PubMedGoogle Scholar
  47. 47.
    Mortola JF, Yen SSC. The effects of oral dehydroepiandrosterone on endocrine-metabolic parameters in postmenopausal women. J Clin Endocr Metab 71:696–704, 1990.PubMedGoogle Scholar
  48. 48.
    Casson PR, Faquin CC, Stentz FB, et al. Replacement of dehydroepiandrosterone enhances T-lymphocyte insulin binding in postmenopausal women. Fertil Steril 63:1027–31, 1995.PubMedGoogle Scholar
  49. 49.
    Morales AJ, Nolan JJ, Nelson JC, Yen SSC. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocr Metab 78:1360–67, 1994.PubMedGoogle Scholar
  50. 50.
    Zumoff B, Strain GW, Heymsfield SB, Lichtman S. A randomized double-blind crossover study of the antiobesity effects of etiocholanedione. Obes Res 2:13–8, 1994.PubMedGoogle Scholar
  51. 51.
    Buffington CK, Pourmotabbed G, Kitabchi AE. Case report: Amelioration of insulin resistance in diabetes with dehydroepiandrosterone. Am J Med Sci 306:320–4, 1993.PubMedGoogle Scholar
  52. 52.
    Orentreich N, Brind JL, Rizer RL, Vogelman JH. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J Clin Endocr Metab 59:551–5, 1984.PubMedGoogle Scholar
  53. 53.
    Carlstrom K, Brody S, Lunell NO, et al. Dehydroepiandrosterone sulphate and dehydroepiandrosterone in serum: Differences related to age and sex. Maturitas 10:297–306, 1988.PubMedGoogle Scholar
  54. 54.
    Orentreich N, Brind JL, Vogelnab JH, et al. Long-term longitudinal measurements of plasma dehydroepiandrosterone sulfate in normal men. J Clin Endocr Metab 75:1002–4, 1992.PubMedGoogle Scholar
  55. 55.
    Parker LN. Adrenal androgens in clinical medicine. Academic Press, San Diego pp 118–34, 1989.Google Scholar
  56. 56.
    Ebeling P, Koivisto VA. Physiological importance of dehydroepiandrosterone. Lancet 343:1479–81, 1994.PubMedGoogle Scholar
  57. 57.
    Nafziger AN, Herrington DM, Bush TL. Dehydroepiandrosterone and dehydroepiandrosterone sulfate: Their relationship to cardiovascular disease. Epidem Rev 13:267–93, 1991.Google Scholar
  58. 58.
    Nestler JE, Mlanahan MA. Diabetes and adrenal disease. Balliere’s Clin Endocr Metab 6:829–7, 1992.Google Scholar
  59. 59.
    Nestler JE, Clore JN, Blackard WG. Dehydroepiandrosterone: The “missing link” between hyperinsulinemia and atherosclerosis. FASEB J 6:3073–75, 1992.PubMedGoogle Scholar
  60. 60.
    Barrett-Connor E, Khaw KT, Yen SSC. A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease. N Engl J Med 315:1519–24, 1986.PubMedGoogle Scholar
  61. 61.
    Khaw KT, Barrett-Connor E. Fasting plasma glucose and endogenous androgens in non-diabetic postmenopausal women. Clin Sci 80:199–203, 1991.PubMedGoogle Scholar
  62. 62.
    Barrett-Connor E. Lower endogenous androgen levels and dyslipidemia in men with non-insulin-dependent diabetes mellitus. Ann Intern Med 117:807–11, 1992.PubMedGoogle Scholar
  63. 63.
    Herrington DM, Gordon GB, Achuff SC, et al. Plasma dehydroepiandrosterone sulfate in patients undergoing diagnostic coronary angiography. J Am Coll Cardiol 16:862–70, 1990.PubMedGoogle Scholar
  64. 64.
    Nyholm H, Djursing H, Hagen C, et al. Androgens and estrogens in postmenopausal insulin-treated diabetic women. J Clin Endocr Metab 69:946–9, 1989.PubMedGoogle Scholar
  65. 65.
    Szpunar WE, Blair AJ, Mann DS. Plasma androgen concentrations in diabetic women. Diabetes 26:1125–29, 1977.PubMedGoogle Scholar
  66. 66.
    Remer T, Pietrzik K. Chronic insulin treatment, but not chronic ACTH administration increases plasma dehydroepiandrosterone sulfate levels in adolescent male rats. Exp Clin Endocr 101:222–9, 1993.Google Scholar
  67. 67.
    Dlue TJ, Shah SC, Marchese M, Malone JI. Insulin resistance and hyperinsulinemia induce hyperandrogenism in a young type B insulin-resistant female. J Clin Endocr Metab 72:1308–11, 1991.Google Scholar
  68. 68.
    Chang RJ, Nakamura RM, Judd HL, Kaplan SA. Insulin resistance in nonobese patients with polycystic ovarian disease. J Clin Endocr Metab 57:356–9, 1983.PubMedGoogle Scholar
  69. 69.
    Shoupe D, Kumar DD, Lobo RA. Insulin resistance in polycystic ovarian syndrome. Am J Obstet Gynecol 147:588–92, 1983.PubMedGoogle Scholar
  70. 70.
    Smith S, Ravnikar VA, Barbieri RL. Androgen and insulin response to an oral glucose challenge in hyperandrogenic women. Fertil Steril 48:72–7, 1987.PubMedGoogle Scholar
  71. 71.
    Vidal-Puig A, Munoz-Torres M, Jodar-Gimeno E, et al. Hyperinsulinemia in polycystic ovary syndrome: Relationship to clinical and hormonal factors. Clin Invest 72:853–7, 1994.Google Scholar
  72. 72.
    Falcone T, Finegood DT, Fantu G, Morris D. Androgen response to endogenous insulin secretion during the frequently sampled intravenous glucose test in normal and hyperandrogenic women. J Clin Endocr Metab 71:1653–57, 1990.PubMedGoogle Scholar
  73. 73.
    Farah MJ, Givens JR, Kitabchi AE. Bimodal correlation between circulating insulin level and production of rate of dehydroepiandrosterone: Positive correlation in controls and negative correlation in polycystic ovary syndrome with acanthosis nigricans. J Clin Endocr Metab 70:1075–81, 1990.PubMedGoogle Scholar
  74. 74.
    Tropeano G, Lucisano A, Liberale I, et al. Insulin, C-peptide, androgens, and b-endorphin response to oral glucose in patients with polycystic ovary syndrome. J Clin Endocr Metab 78:305–9, 1994.PubMedGoogle Scholar
  75. 75.
    Azziz R, Bradley EL, Potter HD, et al. Chronic hyperinsulinemia and the adrenal androgen response to acute corticotrophin-(1–24) stimulation in hyperandrogenic women. Am J Obstet Gynecol 172:1251–56, 1995.PubMedGoogle Scholar
  76. 76.
    Toscano V, Bianchi P, Balducci R, et al. Lack of linear relationship between hyperinsulinemia and hyperandrogenism. Clin Endocr 36:197–207, 1992.PubMedGoogle Scholar
  77. 77.
    Buffington CK, Givens JR, Kitabchi AE. Opposing actions of dehydroepiandrosterone and testosterone on insulin sensitivity. In vivo and in vitro studies in hyperandrogenic females. Diabetes 40:693–700, 1991.PubMedGoogle Scholar
  78. 78.
    Dunaif A, Graf M, Mandeli J, et al. Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose intolerance, and/or hyperinsulinemia. J Clin Endocr Metab 65:499–507, 1987.PubMedGoogle Scholar
  79. 79.
    Schriock ED, Buffington CK, Hubert GD, et al. Divergent correlations of circulating dehydroepiandrosterone and insulin receptor sulfate and testosterone with insulin levels binding. J Clin Endocr Metab 66:1329–31, 1988.PubMedGoogle Scholar
  80. 80.
    Buffington CK, Givens JR, Kitabchi AE. Enhanced adrenocortical activity as a contributing factor to diabetes in hyperandrogenic women. Metabolism 43:584–90, 1994.PubMedGoogle Scholar
  81. 81.
    Schriock ED, Buffington CK, Givens JR, Buster JE. Enhanced post-receptor insulin effects following dehydroepiandrosterone infusion. J Soc Gynecol Invest 1:74–8, 1994.Google Scholar
  82. 82.
    Diamanti-Kandarakis E, Mitrakou A, Hennes MMI, et al. Insulin sensitivity and antiandrogenic therapy in women with polycystic ovary syndrome. Metabolism 44:525–31, 1995.PubMedGoogle Scholar
  83. 83.
    Vidal-Puig A, Muñoz-Torres M, Garcia-Calvente C, et al. Reduction of endogenous, ovarian and adrenal androgens with ketoconazole does not alter insulin response in the polycystic ovary syndrome. J Endocr Invet 17:647–52, 1994.Google Scholar
  84. 84.
    Weiss DJ, Charles MA, Dunaif A, et al. Hyperinsulinemia is associated with menstrual irregularity and altered serum androgens in Pima Indian women. Metabolism 43:803–7, 1994.PubMedGoogle Scholar
  85. 85.
    Dergola G, Giagulli VA, Garruti G. Low dehydroepiandrosterone circulating levels in premenopausal obese women with very high body mass index. Metabolism 40:187–90, 1991.Google Scholar
  86. 86.
    Haffner SM, Valdez RA, Mykkanen L, et al. Decreased testosterone and dehydroepiandrosterone sulfate concentrations are associated with increased insulin and glucose concentrations in diabetic men. Metabolism 43:599–603, 1994.PubMedGoogle Scholar
  87. 87.
    Phillips GB. Relationship between serum sex hormones and the glucose-insulin-lipid defect in men with obesity. Metabolism 42:116–20, 1993.PubMedGoogle Scholar
  88. 88.
    Pasquali R, Casimirri F, Cantobelli S, et al. Effect of obesity and body fat distribution on sex hormones and insulin in men. Metabolism 40:101–4, 1991.PubMedGoogle Scholar
  89. 89.
    Herranz L, Megia A, Grand C, et al. Dehydroepiandrosterone sulphate, body fat distribution and insulin in obese men. Int J Obes 19:57–60, 1995.Google Scholar
  90. 90.
    Haffner SM, Valdez RA, Stern MP, Katz MS. Obesity, body fat distribution and sex hormones in men. Int J Obes 17:643–9, 1993.Google Scholar
  91. 91.
    Tchernof A, Deprés J-P, Bélanger A, et al. Reduced testosterone and adrenal C19 steroid levels in obese men. Metabolism 44:513–19, 1995.PubMedGoogle Scholar
  92. 92.
    Tchernof A, Després J-P, Dupont A, et al. Relation of steroid hormones to glucose tolerance and plasma insulin levels in men. Diabetes Care 18:292–9, 1995.PubMedGoogle Scholar
  93. 93.
    Parker LN. Adrenal androgens in clinical medicine. Academic Press, San Diego p 615, 1989.Google Scholar
  94. 94.
    Zumoff P, Rosenfeld GW, Strain GW. Sex difference in twenty-four hour mean plasma concentrations of dehydroepiandrosterone (DHA) and dehydroepiandrosterone sulfate (DHAS) and the DHA to DHAS ratio in normal adults. J Clin Endocr Metab 51:330–3, 1980.PubMedGoogle Scholar
  95. 95.
    Nestler JE, Kahwash Z. Sex-specific action of insulin to acutely increase the metabolic clearance rate of dehydroepiandrosterone in humans. J Clin Invest 94: 1484–89, 1994.PubMedGoogle Scholar
  96. 96.
    Haning RV Jr, Carlson IH, Rood CA, et al. Metabolism of dehydroepiandrosterone sulfate (DS) in normal women and women with high DS concentrations. J Clin Endocetab 73:1210–15, 1991.Google Scholar
  97. 97.
    Nestler JE, Clore JN, Strauss III JF, Blackard WG. The effects of hyperinsulinemia on serum testosterone, progesterone, dehydroepiandrosterone sulfate, and Cortisol in normal women and in a woman with hyperandrogenism, insulin resistance, and acanthosis nigricans. J Clin Endocr Metab 64:180–4, 1987.PubMedGoogle Scholar
  98. 98.
    Nestler JE, Usiskin KS, Barlascini CO, et al. Suppression of serum dehydroepiandrosterone sulfate levels by insulin: An evaluation of possible mechanisms. J Clin Endocr Metab 69:1040–46, 1989.PubMedGoogle Scholar
  99. 99.
    Ebeling P, Stenman U-H, Seppälä M, Koivisto VA. Acute hyperinsulinemia, androgen homeostasis and insulin sensitivity in healthy men. J Endocrinol 146:63–9, 1995.PubMedGoogle Scholar
  100. 100.
    Diamond MP, Grainger DA, Laudano AJ, et al. Effect of acute physiological elevation of insulin on circulating androgen levels in nonobese women. J Clin Endocr Metab 72:883–7, 1991.PubMedGoogle Scholar
  101. 101.
    Hubert GD, Schriock ED, Givens JR, Buster JE. Suppression of circulating A4-androstenedione and dehydroepiandrosterone sulfate during oral glucose tolerance test in normal females. J Clin Endocr Metab 73:781–1, 1991.PubMedGoogle Scholar
  102. 102.
    Buyalos RP, Bradley EL, Judd HL, et al. No acute effect of physiological insulin increase on dehydroepiandrosterone sulfate in women with obesity and/or polycystic ovarian disease. Fertil Steril 56:1179–82, 1991.PubMedGoogle Scholar
  103. 103.
    Nestler JE, Mlanahan MA, Clore JN, et al. Insulin inhibits 17, 20-lyase activity in man. J Clin Endocr Metab 74:362–7, 1992.PubMedGoogle Scholar
  104. 104.
    Beer NA, Jakubowicz DJ, Beer RM, et al. Effects of nitrendipine on glucose tolerance and serum insulin and dehydroepiandrosterone sulfate levels in insulin-resistant obese and hypertensive men. J Clin Endocr Metab 76:178–83, 1993.PubMedGoogle Scholar
  105. 105.
    Beer NA, Jakubowicz DJ, Beer RM, Nestler JE. The calcium blocker amlodipine raises serum dehydroepiandrosterone sulfate and androstenedione, but lowers serum Cortisol, in insulin-resistant obese and hypertensive men. J Clin Endocr Metab 76:1464–69, 1993.PubMedGoogle Scholar
  106. 106.
    Nester JE, Barlascini CO, Matt DW, et al. Suppression of serum insulin by diazoxide reduces serum testosterone level in obese women with polycystic ovary syndrome. J Clin Endocr Metab 68:1027–31, 1989.Google Scholar
  107. 107.
    Beer NA, Jakubowicz DJ, Beer RM, Nestler JE. Disparate effects on insulin reduction with diltiazem on serum dehydroepiandrosterone sulfate in obese hypertensive men and women. J Clin Endocr Metab 79:1077–81, 1994.PubMedGoogle Scholar
  108. 108.
    Nestler JE, Beer NA, Jakubowicz DJ, Beer RM. Effects of a reduction in circulating insulin by metformin on serum dehydroepiandrosterone sulfate in nondiabetic men. J Clin Endocr Metab 78:549–54, 1994.PubMedGoogle Scholar
  109. 109.
    Nestler JE, Beer NA, Jakubowicz DJ, et al. Effects of insulin reduction with ben-fluorex on serum dehydroepiandrosterone (DHEA), DHEA sulfate and blood pressure in hypertensive middle-aged and elderly men. J Clin Endocr Metab 80:700–6, 1995.PubMedGoogle Scholar
  110. 110.
    Björntorp P. Hyperandrogenicity in women—a prediabetic condition. J Intern Med 234:579–83, 1993.PubMedGoogle Scholar
  111. 111.
    Stuart CA, Prince MJ, Peters EJ, Meyer WJ. Hyperinsulinemia and hyperandrogenemia: In vivo androgen response to insulin infusion. Obstet Gynecol 69:921–5, 1987.PubMedGoogle Scholar
  112. 112.
    van Weerden WM, Biering HG, van Steenbrugge GJ, et al. Adrenal glands of mouse and rat do not synthesize androgens. Life Sci 50:857–61, 1992.PubMedGoogle Scholar
  113. 113.
    Bélanger B, Bélanger A, Labrie F, et al. Comparison of residual C-19 steroids in plasma and prostatic tissue of human, rat and guinea pig after castration: Unique importance of extratesticular androgens in men. J Steroid Biochem 32:695–8, 1989.PubMedGoogle Scholar
  114. 114.
    Edery M, Carreau S, Simon M-J, Drowdowsky MA. In vitro pregnenolone metabolism by mouse adrenal gland: II—biosynthesis of androgens. Steroids 39:191–200, 1982.PubMedGoogle Scholar
  115. 115.
    Ando S, Aquila S, Beraldi E, et al. Physiological changes in androgen plasma levels with elapsing of time from castration in adult male rats. Horm Metab Res 20:96–9, 1988.PubMedGoogle Scholar
  116. 116.
    Nakashima N, Haji M, Sakai Y, et al. Effecy of dehydroepiandrosterone on glucose uptake in cultured human fibroblasts. Metabolism 44:543–8, 1995.PubMedGoogle Scholar
  117. 117.
    Lardy H, Partridge B, Kneer N, Wei Y. Ergosteroids: Induction of thermogenic enzymes in liver of rats treated with steroids derived from dehydroepiandrosterone. Proc Natl Acad Sci USA 92:6617–19, 1995.PubMedGoogle Scholar

Copyright information

© Birkhäuser Boston 1996

Authors and Affiliations

  • Margot P. Cleary
    • 1
    • 1
  1. 1.The Hormel InstituteUniversity of MinnesotaAustinUSA

Personalised recommendations